BIVI vs. KALA, GLTO, GLYC, FLGC, NNVC, NRBO, APM, ORGS, TCRT, and MEIP
Should you be buying BioVie stock or one of its competitors? The main competitors of BioVie include KALA BIO (KALA), Galecto (GLTO), GlycoMimetics (GLYC), Flora Growth (FLGC), NanoViricides (NNVC), NeuroBo Pharmaceuticals (NRBO), Aptorum Group (APM), Orgenesis (ORGS), Alaunos Therapeutics (TCRT), and MEI Pharma (MEIP). These companies are all part of the "pharmaceutical preparations" industry.
KALA BIO (NASDAQ:KALA) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.
KALA BIO has a beta of -1.75, meaning that its share price is 275% less volatile than the S&P 500. Comparatively, BioVie has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.
BioVie's return on equity of -281.02% beat KALA BIO's return on equity.
KALA BIO received 281 more outperform votes than BioVie when rated by MarketBeat users. Likewise, 66.59% of users gave KALA BIO an outperform vote while only 64.00% of users gave BioVie an outperform vote.
KALA BIO has higher revenue and earnings than BioVie. BioVie is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.
In the previous week, KALA BIO had 3 more articles in the media than BioVie. MarketBeat recorded 4 mentions for KALA BIO and 1 mentions for BioVie. KALA BIO's average media sentiment score of 0.47 beat BioVie's score of 0.21 indicating that BioVie is being referred to more favorably in the news media.
KALA BIO presently has a consensus target price of $18.00, indicating a potential upside of 154.24%. BioVie has a consensus target price of $8.00, indicating a potential upside of 1,548.46%. Given KALA BIO's higher probable upside, analysts clearly believe BioVie is more favorable than KALA BIO.
24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 13.4% of KALA BIO shares are owned by company insiders. Comparatively, 4.8% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
KALA BIO beats BioVie on 12 of the 16 factors compared between the two stocks.
Get BioVie News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
